MaxiVAX

MaxiVAX is a clinical-stage biotechnology company dedicated to providing patient-specific immunomodulatory strategies for cancer treatment. Founded in 2005 by Professor Bernard Mach (former co-founder of the University of Geneva and Biogen, and founder of NovImmune) and Professor Nicolas Mach (Oncology, Geneva), the company is also committed to the effective development of potentially optimal cancer immunotherapies to address significant unmet medical needs and improve outcomes for patients with difficult-to-treat cancers.